Contact us today for a complimentary consultation with a qualified attorney near you.
Epogen is a widely prescribed anemia drug that works to raise hemogoblin—red blood cells that transport oxygen—levels in patients suffering from chemotherapy-induced anemia, chronic kidney failure, and HIV. Epogen, along with Procrit and Aranesp, belong to a class of drugs known as erythropoiesis-stimulating agents (ESAs) that have most recently been linked to several life-threatening side effects. New “black-box” warning labels on the drugs show that Epogen raises the risk of heart failure, blood clots, and stroke in some patients.
If you or someone you love has suffered Epogen heart failure or other serious side effect associated with an anemia drug, you may be entitled to seek compensation for your losses through a product liability lawsuit. Please click here to set up a FREE consultation with an effective and dedicated defective drug litigation attorney who can inform you of your legal rights and maximize your interests.
Epogen Heart Failure Black-Box Warning
After reports from several studies found serious risks associated with the use of anemia drugs, the U.S. Food and Drug Administration ordered drug manufacturer Amgen, Inc. to issue the strongest label warning alerting doctors and patients of these dangers. The black-box warning states the following ESA risks:
Patients with heart disease or kidney failure also have a raised risk of blood clots and death. Those with antibody-mediated anemia are advised against taking Epogen or other ESA altogether.
Epogen Heart Failure and Your Legal Rights
If you or a loved one has suffered Epogen-related heart failure or other grave side effect, it is important to understand your legal rights and options. Please contact us today to find out if you are eligible to recover your damages including medical bills, pain and suffering, and more. An experienced defective drug litigation attorney can evaluate your case FREE of charge and determine the best course of action for you.
More Epogen Resources